Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

Embecta Corp. Common Stock (EMBC)
Embecta Corp. Common Stock
XNAS:EMBC
12.61
0.32%

Ask
$12.91 - 200.00
Bid
$11.27 - 100.00
Low
$12.31
High
$12.88
Open
$12.31
Prev Close
$12.57
52W High
21.48
52W Low
9.2
Volume
526874
Avg Vol (3m)
649752.8
Float
54487858.76
Chart
TendieTensor AI Analysis

Company
Asset Type: Common Stock
SIC Code: 3841
Sector: Health Technology
Industry: Medical Specialties
Date Listed: 03/21/2022
Primary Exchange: XNAS

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Phone: (862) 401-0000
Address: 1209 Orange Street
City: Wilmington
State: DE
Postal Code: 19801
TendieTensor AI Analyst Recommendation:
Fundamentals
Total Employees:
2,100
P/E (TTM)
7.876860
P/B (TTM)
-1.146800
EPS
0.5
Div / Yield
4.704038
Round Lot
100
Composit FIGI
BBG014L7D4G1
Share Class FIGI
BBG014L7D4H0
Share Class Shares Outstanding
58.49M
Weighted Shares Outstanding
58.49M

Technicals
RSI (14)
MACD Line
MACD Signal
SMA 20
SMA 50
EMA 50
Trend
Short Interest
Days to Cover
Higher = harder to cover
Short Interest Δ
Prev: —
Short Volume Ratio (Today)
5D avg:
Squeeze Score (0–100)
Discussion
Login to participate in discussions.
Recent News
Related Stocks

Based on the portfolios of people who own EMBC. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.